[go: up one dir, main page]

AR013994A1 - Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes. - Google Patents

Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.

Info

Publication number
AR013994A1
AR013994A1 ARP980105446A ARP980105446A AR013994A1 AR 013994 A1 AR013994 A1 AR 013994A1 AR P980105446 A ARP980105446 A AR P980105446A AR P980105446 A ARP980105446 A AR P980105446A AR 013994 A1 AR013994 A1 AR 013994A1
Authority
AR
Argentina
Prior art keywords
procedure
osteopathies
selectively modulate
osteoblasto
fragilizing
Prior art date
Application number
ARP980105446A
Other languages
English (en)
Original Assignee
Gador Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gador Sa filed Critical Gador Sa
Priority to ARP980105446A priority Critical patent/AR013994A1/es
Priority to PCT/EP1999/008269 priority patent/WO2000025794A1/en
Priority to JP2000579234A priority patent/JP2003524606A/ja
Priority to KR1020017005472A priority patent/KR20010103632A/ko
Priority to TR2001/01176T priority patent/TR200101176T2/xx
Priority to AU12675/00A priority patent/AU771081B2/en
Priority to CA002346171A priority patent/CA2346171C/en
Priority to US09/830,734 priority patent/US6605603B1/en
Priority to EP99955918A priority patent/EP1137419A1/en
Priority to CN99812911A priority patent/CN1342083A/zh
Publication of AR013994A1 publication Critical patent/AR013994A1/es
Priority to IL142609A priority patent/IL142609A/en
Priority to ZA200103404A priority patent/ZA200103404B/en
Priority to US10/619,729 priority patent/US20040023931A1/en
Priority to IL172603A priority patent/IL172603A/en
Priority to US11/775,297 priority patent/US20070270388A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procedimiento para la administracion de uso médico o veterinario,de ciertas cantidades de bisfosfonatos, inferiores a las conocidas como inhibidoras de laresorcion osea, que sirven para modular selectivamente al osteoblasto y prevenir y tratar las osteopatías fragilizantes. Se prefiere el bisfofonato deformula I denominado IG-9402 químicamente: el ácido 3-(N, N-dimetilamino)-1- aminopropiliden-bisfosfonico y sus sales solubles e hidratos en dosis por vezde 1000 mg o menos por vía oral, y 200mg o menos por vía parenteral. Comprende los usos industriales y tecnologicos de los productos y formulacionesdesarrolladas en base a este procedimietno y sus combinaciones con otros conocidos. Se demuestra el efecto selectivo estimulante sobre la actividadgenomica y no genomica del osteoblasto.
ARP980105446A 1998-10-30 1998-10-30 Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes. AR013994A1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
ARP980105446A AR013994A1 (es) 1998-10-30 1998-10-30 Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
US09/830,734 US6605603B1 (en) 1998-10-30 1999-10-29 Uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid
EP99955918A EP1137419A1 (en) 1998-10-30 1999-10-29 Uses of 1-amino-3-(n,n-dimethylamino)-propylidene-1,1-bisphosphonic acid
KR1020017005472A KR20010103632A (ko) 1998-10-30 1999-10-29 1-아미노-3-(엔,엔-디메틸아미노)-프로필리덴-1,1-비스포스폰산의 용도
TR2001/01176T TR200101176T2 (tr) 1998-10-30 1999-10-29 1-Amino-3-(N,N-Dimetilamino)-Propiliden-1,1-Bisfosfonik asidin kullanımları
AU12675/00A AU771081B2 (en) 1998-10-30 1999-10-29 Uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid
CA002346171A CA2346171C (en) 1998-10-30 1999-10-29 Uses of 1-amino-3-(n,n-dimethylamino)-propylidene-1,1-bisphosphonic acid
PCT/EP1999/008269 WO2000025794A1 (en) 1998-10-30 1999-10-29 Uses of 1-amino-3-(n,n-dimethylamino)-propylidene-1,1-bisphosphonic acid
JP2000579234A JP2003524606A (ja) 1998-10-30 1999-10-29 １−アミノ−３−（ｎ，ｎ−ジメチルアミノ）−プロピリデン−１，１−ビスホスホン酸の使用
CN99812911A CN1342083A (zh) 1998-10-30 1999-10-29 1－氨基－3－(n,n－二甲基氨基)－亚丙基－1,1－双膦酸的应用
IL142609A IL142609A (en) 1998-10-30 2001-04-15 Uses of 1 - amino-3- (n,n-dimethylamino) - propylidene - 1,1 - bisphosphonic acid for manufacturing medicaments for stimulating cellular activities of osteoblasts
ZA200103404A ZA200103404B (en) 1998-10-30 2001-04-26 Use of 1-amino-3-(N,N-Dimethylamino)-propylidene-1,1-bisphosphonic acid.
US10/619,729 US20040023931A1 (en) 1998-10-30 2003-07-15 Uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid
IL172603A IL172603A (en) 1998-10-30 2005-12-15 Use of 1 - amino - n, n) - 3 - dimethylamino) - propylidene - 1,1 - bisphosphonic acid and its soluble or hydrated salts for the preparation of drugs to stimulate cellular activities of osteoblasts
US11/775,297 US20070270388A1 (en) 1998-10-30 2007-07-10 Uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP980105446A AR013994A1 (es) 1998-10-30 1998-10-30 Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.

Publications (1)

Publication Number Publication Date
AR013994A1 true AR013994A1 (es) 2001-01-31

Family

ID=41030398

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105446A AR013994A1 (es) 1998-10-30 1998-10-30 Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.

Country Status (12)

Country Link
US (3) US6605603B1 (es)
EP (1) EP1137419A1 (es)
JP (1) JP2003524606A (es)
KR (1) KR20010103632A (es)
CN (1) CN1342083A (es)
AR (1) AR013994A1 (es)
AU (1) AU771081B2 (es)
CA (1) CA2346171C (es)
IL (2) IL142609A (es)
TR (1) TR200101176T2 (es)
WO (1) WO2000025794A1 (es)
ZA (1) ZA200103404B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
EP1758594A1 (en) * 2004-05-19 2007-03-07 Merck and Co., Inc. Combination for inhibiting bone resorption comprising a bisphosponate (alendrona) and a vitamin d (cholecalciferol)
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
US20070098819A1 (en) * 2005-11-02 2007-05-03 Susan Thys-Jacobs Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
US9334300B2 (en) 2011-08-01 2016-05-10 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114473T1 (de) * 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
HU215124B (hu) * 1991-02-26 1998-09-28 Norwich Eaton Pharmaceuticals, Inc. Eljárás csontritkulás (osteoporosis) kezelésére szolgáló ösztrogént és difoszfonátot tartalmazó, szinergetikus hatású gyógyszerkészítmények előállítására
JP4481368B2 (ja) * 1992-06-30 2010-06-16 味の素株式会社 骨粗鬆症の治療用のためのホスホネート類の用途
US5635495A (en) * 1992-10-09 1997-06-03 The Upjohn Company Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
AU8083694A (en) * 1993-10-19 1995-05-08 Merck & Co., Inc. Combination of bisphosphonates and growth hormone secretagogues
BR9510123A (pt) * 1994-12-28 1997-12-30 Gador Sa Composição anabólica da massa óssea
EP0753523A1 (en) * 1995-07-10 1997-01-15 Gador S.A. Amino-substituted bisphosphonic acids
CA2271664A1 (en) * 1996-11-25 1998-06-04 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases

Also Published As

Publication number Publication date
IL142609A (en) 2006-07-05
ZA200103404B (en) 2002-03-14
TR200101176T2 (tr) 2002-02-21
IL172603A (en) 2013-06-27
EP1137419A1 (en) 2001-10-04
KR20010103632A (ko) 2001-11-23
WO2000025794A1 (en) 2000-05-11
CN1342083A (zh) 2002-03-27
JP2003524606A (ja) 2003-08-19
AU1267500A (en) 2000-05-22
US20040023931A1 (en) 2004-02-05
AU771081B2 (en) 2004-03-11
CA2346171C (en) 2006-01-17
US6605603B1 (en) 2003-08-12
US20070270388A1 (en) 2007-11-22
IL172603A0 (en) 2006-04-10
CA2346171A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
ES2191048T3 (es) Derivados de oxazolidinona y compuestos farmaceuticos que los contienen.
AR013994A1 (es) Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
CO5271691A1 (es) Nuevos compuestos
CY1108105T1 (el) Ιβανδρονικο οξυ για την θεραπευτικη αντιμετωπιση και την προληψη της οστεoπορωσης
ECSP034914A (es) "azaindoles"
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
GEP20032925B (en) Benzothiepines Having Activity As Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake
BR0015624A (pt) Uso de um composto, composto, composição farmacêutica, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR9813926A (pt) Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
AR020662A1 (es) Compuestos dihidrotiazoles policiclicos, procedimientos para su preparacion, medicamento, procedimiento para la preparacion de dicho medicamento y lautilizacion de dichos compuestos para la preparacion de un medicamento.
PA8529501A1 (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."
AR010700A1 (es) Derivados de purina sustituidos, procedimiento para su preparacion, su empleo y su agente que los contiene
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
UY25950A1 (es) Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea

Legal Events

Date Code Title Description
FB Suspension of granting procedure